Work

25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.03.040

Authors: F. Brasó-Maristany, O. Martinez Saez, L. Pare Brunet, M. Marín-Aguilera, P.F. Conte, P. Jares, V. Guarneri, T. Pascual, J.A. Puig-Butille, A. Vivancos, J. Parker, P. Villagrasa Gonzalez, S.M. Tolaney, L.A. Carey, C.M. Perou, A. Prat

Institutions: Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Hospital Clínic de Barcelona, Istituto Oncologico Veneto, University of Padua, Vall d'Hebron Hospital Universitari, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Exelixis, Les Laboratories Pierre Fabre, Mersana Therapeutics, Syndax Pharmaceuticals, G1 Therapeutics, Seagen, Eisai, Genentech, Chugai Pharmaceutical, Daiichi Sankyo Europe

OpenAlex ID: W4229077799

FWCI: 0.09

Cites: 1

Cited by: 1

Related to: 10